According to FutureWise analysis, the immuno-oncology market in 2025 is US$32.45 billion, and is expected to reach US$124.9 billion by 2033 at a CAGR of 18.35%.The Immuno-Oncology market is experiencing rapid growth due to the increasing global burden of cancer and the rising success of immunotherapies, such as checkpoint inhibitors and CAR-T cell therapies. Advances in precision medicine and biomarker research are facilitating the development of more targeted and effective treatments. Strategic collaborations between biotech firms and pharmaceutical companies are accelerating the drug development process. Furthermore, regulatory approvals for novel therapies and expanded indications are contributing to market expansion across various cancer types.
The increasing incidence of cancer, coupled with significant advancements in technology—especially in molecular techniques—has significantly impacted the landscape of cancer diagnostics. Extensive research initiatives and ongoing clinical trials in the domain of cancer immunotherapy are expected to further accelerate the growth of the immuno-oncology assays market. According to the World Health Organization (WHO), cancer was responsible for approximately 8.8 million deaths globally, accounting for one in every six deaths. This stark reality underscores the urgent need for effective cancer management strategies, driving the demand for personalized medicine solutions and, consequently, the immuno-oncology assays market during the forecast period.
The advent of highly sensitive molecular techniques, such as next-generation sequencing (NGS) and digital PCR (dPCR), has transformed how researchers and clinicians analyze circulating biomarkers. These innovative technologies enable the detection of genetic material, proteins, and other indicators of disease progression with remarkable accuracy and specificity. This not only aids in early diagnosis but also allows for tailored therapeutic approaches based on individual patient profiles.
Furthermore, the minimally invasive nature of these diagnostic methods, which often rely on blood samples rather than more invasive tissue biopsies, makes the process more accessible and comfortable for patients. As these cutting-edge tools continue to evolve, they provide a cost-effective means to enhance diagnosis, refine prognostic markers, and facilitate therapy selection throughout a patient’s treatment journey. As a result, the global market for immuno-oncology assays is expected to see substantial growth as healthcare providers increasingly adopt these advanced methodologies to improve patient outcomes.
FutureWise Market Research has published a report that provides an insightful analysis of Immuno-Oncology Market trends that are affecting the overall market growth.

Request a Free Sample @ https://www.futurewiseresearch.com/contact.aspx?rpt=10981&type=requestsample
Immuno-Oncology Market Segmentation:
By Product Class
• Monoclonal Antibodies
o Naked Monoclonal Antibodies
 Rituxan (Rituximab)
 Avastin (Bevacizumab)
 Herceptin (Trastuzumab)
o Conjugated Monoclonal Antibodies
 ADCETRIS (Brentuximab vedotin)
 Kadcyla (Ado-trastuzumab emtansine/TDM-1)
o Bispecific Monoclonal Antibodies
 Blincyto (Blinatumomab)
o Others
• Therapeutic Vaccines
o Provenge
• Immune Checkpoint Inhibitors
o CTLA-4 Inhibitors (Cytotoxic T-lymphocyte-associated Protein-4)
 Yervoy (Ipilimumab)
o PD-1 and PD-L1 Inhibitors(Programmed Death 1 and Programmed Death Ligand)
 Opdivo (Nivolumab)
 Keytruda (Pembrolizumab)
• Others



By Major Indications

• Head And Neck Cancer
• Lung Cancer
• Melanoma
• Lymphoma
• Leukemia
• Others

By Region
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Competitive Landscape in Immuno-Oncology Market:
• F. Hoffmann-La Roche AG
• Bristol-Myers Squibb
• MerckCo Co., Inc.
• Novartis
• AstraZeneca Plc
• Pfizer Inc
• Eli Lilly and Company
• Johnson And Johnson
• Amgen Inc.

Buy now the latest version of this report: https://www.futurewiseresearch.com/checkout.aspx?ReportId=10981&license=multi


**Objectives of this Study: **
1. To provide a comprehensive analysis of the Immuno-Oncology Market By Product Class, By Major Indications and By Region.
2. To offer detailed insights into factors such as drivers, restraints, trends, and opportunities, as well as segmental and regional influences on market growth.
3. To evaluate current market trends and forecast micro-markets, presenting overall market projections in the form of data sets and PowerPoint presentations.
4. To predict the market size in key regions, including North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of contents as per your requirement
• The customization services offered are free of charge with the purchase of any license of the report.
• You can directly share your requirements/changes to the current table of contents to: [email protected]

FutureWise Research
Contact Person: Vinay Thaploo.
Email: [email protected]
Contact Number: Asia: +91 8605575209 | UK: +44 0113 519 7222
Website: www.futurewiseresearch.com